2992对T790M的活性很弱,所以有联合西妥昔单抗延迟2992耐药的用法出来,缺点是性价比偏低,PFS、ORR等数据还待临床揭晓;
《Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.》
2992对T790M的活性很弱,所以有联合西妥昔单抗延迟2992耐药的用法出来,缺点是性价比偏低,PFS、ORR等数据还待临床揭晓;
《Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.》